CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
Visterra›
Library
Visterra

Visterra

Visterra develops antibody-based biologic therapies for kidney and other hard-to-treat diseases as an Otsuka subsidiary.

Operating headquarters
Waltham, MA, US🇺🇸
Founded
2008
Loading
Overview
M & A
Analysis
Compare
Fundraising
Employees
News
Library

Visterra - Library

visterrainc.com·Crawled Oct 1, 2026·

Topics

Publication type

Content origin
Row density

Product

2 pages
  1. Clinical Trials/for-patients/clinical-trials

    We design and run innovative and nimble pre-clinical studies and early phase clinical trials to answer critical questions about safety, tolerability, dosing regimen, pharmacokinetics, pharmacodynamics, biomarkers, and efficacy.

  2. Overview/pipeline/overview

Blog

6 pages
  1. A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy/visterra_pubs/a-proliferation-inducing-ligand-april-targeted-antibody-is-a-safe-and-effective-treatment-of-murine-iga-nephropathy

    James R Myette, Toshiki Kano, Hitoshi Suzuki, Susan E Sloan, Kristy J Szretter, Boopathy Ramakrishnan, Hedy Adari, Ketan D Deotale, Frank Engler, Zachary Shriver, Andrew M Wollacott, Yusuke Suzuki, Brian J G Pereira

  2. Conferences/our-research/conferences
  3. Modeling cell-specific dynamics and regulation of the common gamma chain cytokines/visterra_pubs/modeling-cell-specific-dynamics-and-regulation-of-the-common-gamma-chain-cytokines

    Ali M. Farhat, Adam C. Weiner, Cori Posner, Zoe S. Kim, Brian Orcutt-Jahns, Scott M. Carlson, Aaron S. Meyer

  4. Our Approach/our-research/our-approach

    We use our biological insight, along with structure considerations and knowledge of the biology and molecular function, to identify specific epitopes to engage.

Press

2 pages
  1. Effect of Sibeprenlimab on eGFR in Adults With IgA Nephropathy: A Prespecified Interim Analysis of the VISIONARY Phase 3 Trial/visterra_present/effect-of-sibeprenlimab-on-egfr-in-adults-with-iga-nephropathy-a-prespecified-interim-analysis-of-the-visionary-phase-3-trial
  2. Sibeprenlimab for Patients With IgA Nephropathy: Results From a Prespecified Interim Analysis of the Phase 3 VISIONARY Study/visterra_present/sibeprenlimab-for-patients-with-iga-nephropathy-results-from-a-prespecified-interim-analysis-of-the-phase-3-visionary-study

    Vlado Perkovic, Jonathan Barratt, Richard Lafayette, Adrian Liew, Yusuke Suzuki, Kevin Carroll, Chee Kay Cheung, Vladimir Tesař, Hernán Trimarchi, Muh Geot Wong, Hong Zhang, Dana V. Rizk

Careers & Hiring

3 pages
  1. Co-op program/careers/co-op-program

    Co-ops work directly on our research discovery programs, computational platform, technology platform, or with our manufacturing team

  2. Open Positions & Benefits/careers/open-positions-benefits

    Do you want to make a positive impact on people’s lives through better medicine with a team that champions innovation, teamwork, and perseverance?

  3. Our Culture/careers/our-culture

    We are intentional about supporting and growing our culture where people can invent, discover, and have fun along the way.

Team

6 pages
  1. Bender, Jean L/visterra_people/bender-jean-l

    As Vice President, Pharmaceutical Sciences and Technology, Jean Bender is accountable for leading all CMC activities for Visterra's product pipeline.

  2. Kuniholm, Jeffrey/visterra_quotes/kuniholm-jeffrey

    “The supportive environment and scientific expertise at Visterra made me a better researcher during my time as a Research Associate. The skills I developed emboldened me to pursue my PhD. I am incredibly excited to return to Visterra to make impactful contributions to the research programs and to mentor junior scientists.” – Jeffrey Kuniholm, Principal... READ MORE>>

  3. Leadership Team/about-us/leadership-team

    As Chief Scientific Officer, Greg Babcock is responsible for strategic leadership of all areas of research for the company. Greg joined Visterra in 2013 and has 25 years of experience researching and developing monoclonal antibodies for a variety of disease indications. Previously, Greg served as the Deputy Director of MassBiologics, building and leading the research… READ MORE>>

  4. Robinson, Luke/visterra_quotes/robinson-luke

    “At Visterra, there is a great culture of empowering individuals to provide meaningful input to all aspects of the science and decision-making. I am constantly amazed by others’ innovative ideas, and I enjoy being part of highly collaborative teams that translate these creative ideas into products that have a real impact on patients.” – Luke... READ MORE>>

About

1 page
  1. Our Vision/about-us/our-vision

    We aim to be a best-in-class biologics center of excellence, consistently developing and delivering transformative medicines to patients.

Contact

1 page
  1. Contact/contact

    275 Second Ave. 4th Floor Waltham, MA 02451

Homepage

1 page
  1. Homepage/

    Visterra is a biologics research and early-stage clinical development company developing therapies for patients with immune-mediated and other hard-to-treat diseases.

Privacy

1 page
  1. Privacy Policy/privacy-policy

    Visterra, Inc. (“Visterra,” “we,” “us,” or “our) recognizes and respects the privacy rights of individuals regarding their personal data. This policy describes how we collect, use, share and secure your personal data and choices and rights you may have regarding your data. This policy applies to personal data that we collect through our websites and from other sources.

Terms & Conditions

1 page
  1. Terms of Use/terms-of-use

    Welcome to the Visterra, Inc. website. These terms govern your use of the site. By visiting our site, you agree to these terms.

Coverage

5 items
  1. Nona Biosciences and Visterra Partner to Advance Next-Generation Biotherapeutics for Immune-Mediated and Autoimmune Diseasesprnewswire.com/news-releases/nona-biosciences-and-visterra-partner-to-advance-next-generation-biotherapeutics-for-immune-mediated-and-autoimmune-diseases-302480195.html

    Nona Biosciences announces a license agreement with Visterra to advance next-generation biotherapeutics for immune-mediated and autoimmune diseases. The partnership's stated purpose is to progress biotherapeutic development in these disease areas, applying a next-generation approach to treatments for immune-mediated and autoimmune conditions.

    Jun 2025 · PR Newswire / Nona BiosciencesNews article

  2. Nona Biosciences and Visterra Partner to Advance Next-Generation Biotherapeuticsnonabio.com/nona-biosciences-and-visterra-partner-to-advance-next-generation-biotherapeutics-for-immune-mediated-and-autoimmune-diseases/

    Nona Biosciences announces a license agreement with Visterra to advance Visterra’s next-generation biotherapeutic pipeline for immune-mediated and autoimmune diseases.

    Jun 2025 · Nona BiosciencesNews article

  3. Otsuka has high hopes for its 'drug creation engine' acquisitionpharmaphorum.com/news/otsuka-biotech-visterra-hierotope

    Otsuka announces a $430 million acquisition of Visterra. The acquisition is characterized as a “drug creation engine,” but the supplied text provides no further details about the deal or Visterra’s technology.

    Jul 2018 · pharmaphorumNews article

  4. Otsuka Pharmaceutical to Acquire Visterraotsuka-us.com/discover/articles-1206

    Otsuka Pharmaceutical agrees to acquire Visterra for approximately $430 million under a definitive merger agreement. Visterra continues operating as a wholly owned Otsuka subsidiary in Waltham.

    Jul 2018 · Otsuka USNews article